Edwards, Gabriel G. http://orcid.org/0000-0002-1083-0919
Miyashita-Ochoa, Ayako
Castillo, Enrico G.
Goodman-Meza, David
Kalofonos, Ippolytos
Landovitz, Raphael J.
Leibowitz, Arleen A.
Pulsipher, Craig
El Sayed, Ed
Shoptaw, Steven
Shover, Chelsea L.
Tabajonda, Michelle
Yang, Yvonne S.
Harawa, Nina T.
Funding for this research was provided by:
Office of the President, University of California (RP15-LA-007)
National Institute of Mental Health (MH58107, K23MH125201)
Clinical and Translational Science Institute, University of California, Los Angeles (UL1TR0001881)
The Friends of Semel Institute for Neuroscience and Human Behavior at UCLA
National Institute on Drug Abuse (K01-DA050771)
Article History
Accepted: 16 August 2022
First Online: 5 September 2022
Declarations
:
: Steven Shoptaw has received clinical support for his research from Gilead Sciences, Inc. Raphael Landovitz serves on the Scientific Advisory Board for Gilead Sciences and Merck, Inc, and received honoraria for symposium presentations at Cepheid and Janssen Pharmaceuticals. Nina T. Harawa has received honoraria for two recent speaking engagements sponsored by Gilead Sciences, Inc. She also is a member of the Scientific Advisory Board for the Black AIDS Institute and a co-investigator, with in-kind support, on a Gilead Sciences-focused on HIV prevention center. The authors have no further conflicts of interest or competing interests to declare.
: This work did not include human subjects and has not been approved by an institutional review board.
: N/A.
: N/A.